Cardiff Oncology Inc (CRDF) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: -$4.6M

CRDF ranks #4459 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

106 institutions disclose a position in CRDF, but none treat it as a major bet — even Pfizer Inc, its most concentrated holder, allocates just 1.8% of its own portfolio to it.

UBS Group AG has added to its CRDF position for two straight quarters, increasing it by $584.6K to reach $830.3K today.

BlackRock has trimmed its CRDF position for two straight quarters, cutting it by $10.1M while still holding $1.3M.

CRDF is up 2.9% today, but institutions show net selling of $4.6M this quarter — a divergence between today's price move and the underlying institutional flow.

CRDF reported a net loss of $40.1M over the trailing twelve months.

• Not yet profitable — net loss of $40.1M over the trailing twelve months
• Revenue declined 7.0% year over year
• Net income improved year over year, from -$51.0M to -$40.1M
• Operating cash flow was negative, using $37.9M in cash
• Current ratio of 3.67x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.36x equity — within a conventional range